Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Am J Epidemiol ; 191(7): 1174-1179, 2022 Jun 27.
Article in English | MEDLINE | ID: covidwho-1758623

ABSTRACT

Nearly every introductory epidemiology course begins with a focus on person, place, and time, the key components of descriptive epidemiology. And yet in our experience, introductory epidemiology courses were the last time we spent any significant amount of training time focused on descriptive epidemiology. This gave us the impression that descriptive epidemiology does not suffer from bias and is less impactful than causal epidemiology. Descriptive epidemiology may also suffer from a lack of prestige in academia and may be more difficult to fund. We believe this does a disservice to the field and slows progress towards goals of improving population health and ensuring equity in health. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak and subsequent coronavirus disease 2019 pandemic have highlighted the importance of descriptive epidemiology in responding to serious public health crises. In this commentary, we make the case for renewed focus on the importance of descriptive epidemiology in the epidemiology curriculum using SARS-CoV-2 as a motivating example. The framework for error we use in etiological research can be applied in descriptive research to focus on both systematic and random error. We use the current pandemic to illustrate differences between causal and descriptive epidemiology and areas where descriptive epidemiology can have an important impact.


Subject(s)
COVID-19 , Epidemiology , Pandemics , COVID-19/epidemiology , Disease Outbreaks , Epidemiology/standards , Humans , Public Health , SARS-CoV-2
2.
Math Biosci ; 333: 108545, 2021 03.
Article in English | MEDLINE | ID: covidwho-1033643

ABSTRACT

The SARS-CoV-2 virus has spread across the world, testing each nation's ability to understand the state of the pandemic in their country and control it. As we looked into the epidemiological data to uncover the impact of the COVID-19 pandemic, we discovered that critical metadata is missing which is meant to give context to epidemiological parameters. In this review, we identify key metadata for the COVID-19 fatality rate after a thorough analysis of mathematical models, serology-informed studies and determinants of causes of death for the COVID-19 pandemic. In doing so, we find reasons to establish a set of standard-based guidelines to record and report the data from epidemiological studies. Additionally, we discuss why standardizing nomenclature is be a necessary component of these guidelines to improve communication and reproducibility. The goal of establishing these guidelines is to facilitate the interpretation of COVID-19 epidemiological findings and data by the general public, health officials, policymakers and fellow researchers. Our suggestions may not address all aspects of this issue; rather, they are meant to be the foundation for which experts can establish and encourage future guidelines throughout the appropriate communities.


Subject(s)
COVID-19/epidemiology , COVID-19/mortality , Health Communication/standards , Pandemics , SARS-CoV-2 , COVID-19 Serological Testing/statistics & numerical data , Epidemiology/standards , Epidemiology/statistics & numerical data , Epidemiology/trends , Humans , Mathematical Concepts , Metadata/standards , Models, Statistical , Public Health/standards , Public Health/statistics & numerical data , Public Health/trends , Reproducibility of Results , Risk Factors , Seroepidemiologic Studies , United States/epidemiology
3.
Contemp Clin Trials ; 102: 106214, 2021 03.
Article in English | MEDLINE | ID: covidwho-917234

ABSTRACT

Most crises, though difficult and challenging to address, offer opportunities for change and for development of new perspectives or approaches to deal with traditional strategies. The reaction to and the managing of the COVID-19 pandemic has provided a platform for evaluating how we quantify disease prevalence, incidence, time courses and sequellae as well as how well we plan, design, analyze and interpret health care associated data, including clinical trials and electronic medical records and health claims data. Whether the Covid-19 crisis provides opportunities to advance the fields of biostatistics and epidemiology in select ways remains to be seen. This article describes three areas of crises experienced by the author during a career in the regulation of pharmaceutical products and how they were responded to. Some suggestions for potential future opportunities in reaction to the Covid-19 crises are provided.


Subject(s)
Biostatistics , COVID-19/epidemiology , Data Collection/methods , Epidemiology/organization & administration , Acquired Immunodeficiency Syndrome/drug therapy , Acquired Immunodeficiency Syndrome/epidemiology , Anti-HIV Agents/therapeutic use , Clinical Trials as Topic/organization & administration , Cooperative Behavior , Data Collection/standards , Drug Development/organization & administration , Drug Industry/organization & administration , Efficiency, Organizational , Epidemiology/standards , Humans , Incidence , Pandemics , Prevalence , SARS-CoV-2 , Time Factors , United States , United States Food and Drug Administration/organization & administration
4.
J Am Acad Dermatol ; 83(6): 1704-1716, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-744059

ABSTRACT

OBJECTIVE: To provide guidance about management of psoriatic disease during the coronavirus disease 2019 (COVID-19) pandemic. STUDY DESIGN: A task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care was convened. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation (NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by questions received by the NPF. A Delphi process was conducted. RESULTS: The TF approved 22 guidance statements. The average of the votes was within the category of agreement for all statements. All guidance statements proposed were recommended, 9 with high consensus and 13 with moderate consensus. LIMITATIONS: The evidence behind many guidance statements is limited in quality. CONCLUSION: These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk and outcome, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 and what they should do if they develop COVID-19. The guidance is intended to be a living document that will be updated by the TF as data emerge.


Subject(s)
Coronavirus Infections/epidemiology , Immunosuppressive Agents/adverse effects , Organizations, Nonprofit/standards , Pneumonia, Viral/epidemiology , Psoriasis/drug therapy , Advisory Committees/standards , Betacoronavirus/immunology , Betacoronavirus/pathogenicity , COVID-19 , Consensus , Coronavirus Infections/immunology , Coronavirus Infections/prevention & control , Coronavirus Infections/virology , Critical Care/standards , Delphi Technique , Dermatology/standards , Epidemiology/standards , Humans , Infectious Disease Medicine/standards , Organizations, Nonprofit/organization & administration , Pandemics/prevention & control , Pneumonia, Viral/immunology , Pneumonia, Viral/prevention & control , Pneumonia, Viral/virology , Psoriasis/complications , Psoriasis/immunology , Rheumatology/standards , SARS-CoV-2 , United States/epidemiology
5.
JMIR Public Health Surveill ; 6(1): e18503, 2020 03 27.
Article in English | MEDLINE | ID: covidwho-18717

ABSTRACT

The World Health Organization (WHO) declared the current COVID-19 a public health emergency of international concern on January 30, 2020. Countries in the Eastern Mediterranean Region (EMR) have a high vulnerability and variable capacity to respond to outbreaks. Many of these countries addressed the need for increasing capacity in the areas of surveillance and rapid response to public health threats. Moreover, countries addressed the need for communication strategies that direct the public to actions for self- and community protection. This viewpoint article aims to highlight the contribution of the Global Health Development (GHD)/Eastern Mediterranean Public Health Network (EMPHNET) and the EMR's Field Epidemiology Training Program (FETPs) to prepare for and respond to the current COVID-19 threat. GHD/EMPHNET has the scientific expertise to contribute to elevating the level of country alert and preparedness in the EMR and to provide technical support through health promotion, training and training materials, guidelines, coordination, and communication. The FETPs are currently actively participating in surveillance and screening at the ports of entry, development of communication materials and guidelines, and sharing information to health professionals and the public. However, some countries remain ill-equipped, have poor diagnostic capacity, and are in need of further capacity development in response to public health threats. It is essential that GHD/EMPHNET and FETPs continue building the capacity to respond to COVID-19 and intensify support for preparedness and response to public health emergencies.


Subject(s)
Capacity Building , Cooperative Behavior , Coronavirus Infections , Disease Outbreaks/prevention & control , Epidemiology/education , Global Health , Pandemics , Pneumonia, Viral , Public Health Surveillance/methods , Public Health/education , Social Networking , Betacoronavirus , COVID-19 , Civil Defense , Coronavirus Infections/epidemiology , Coronavirus Infections/prevention & control , Epidemiology/standards , Health Promotion , Humans , Mediterranean Region , Pandemics/prevention & control , Pneumonia, Viral/epidemiology , Pneumonia, Viral/prevention & control , Public Health/standards , Public Health Practice , SARS-CoV-2 , Workforce
SELECTION OF CITATIONS
SEARCH DETAIL